Victor Tong

LevitasBio is a premier end-to-end sample processing and analysis provider to the life sciences market. Our advanced LeviCell system is a groundbreaking cellular research and analysis tool for scientists, researchers, and labs. For the first time ever, researchers can examine, analyze and understand true biological signatures without altering, stressing, or damaging cells—all while preserving the original samples. LeviCell delivers true biology for real cellular insights to power cellular research.

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships. EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.

Cellular Research, Inc., is a pioneering biotechnology research and development company founded in 2011 by innovators from Silicon Valley and Stanford University. Our mission is to revolutionize life science research by enabling high resolution investigation of single cells and limited samples. Our first two product lines Pixel and Precise deliver the power of Molecular Indexing to customers interested in high accuracy and precision for Gene Expression Studies.

At GenapSys we are working to power the world of healthcare and diagnostics with advanced DNA sequencing technology. Our sequencing instrument platform leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, enabling a wide range of applications including targeted sequencing in oncology, pharmacogenomics and genome-wide sequencing in microbiology and others. We believe in a world where every researcher has a compact, scalable, and affordable sequencer in their own lab, empowering the democratization of genetic sequencing. Our novel sequencing method is revolutionizing genomics discovery, biomedical research, healthcare, diagnostics, agriculture, and a variety of other fields. Our team brings together an incredibly diverse and multidisciplinary set of backgrounds and skills – from electrical and mechanical engineers, physicists, chemists, microfluidic engineers, molecular biologists, bioinformaticians, mathematicians and more. It is a super exciting time to join GenapSys as we recently launched our first product which is generating a tremendous amount of interest.

Ion Torrent has developed a DNA sequencing system that directly translates chemical signals (A, C, G, T) into digital information (0, 1) on a semiconductor chip. The result is a sequencing system that is simpler, faster, more cost effective and scalable than any other technology available. Because Ion Torrent produces its proprietary semiconductor chips in standard CMOS factories, we leverage the $1 trillion dollar investment that has been made in the semiconductor industry over the past 40 years. This enables us to directly benefit from four decades of exponential improvement in semiconductor technology, usually expressed as Moore’s Law. The company was founded in August 2007 by Jonathan Rothberg, a pioneer of high-speed, massively parallel DNA sequencing. Ion Torrent is based in Guilford, Connecticut with offices in San Francisco. Ion Torrent will launch the Ion Personal Genome Machine sequencer in 2010. For more information about Ion Torrent, visit www.lifetechnologies.com/iontorrent

Nevro is a global medical device company focused on delivering innovation to improve the quality of life for patients suffering from debilitating chronic pain. Through HFX, Nevro brings together enduring technologies, optimized therapies, and individualized patient support, all built on a foundation of proof that results in a comprehensive solution to relieve the burden of pain for more patients. HFX is a comprehensive solution that includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain, including painful diabetic neuropathy when programmed with a frequency of 10 kHz.

LevitasBio is a premier end-to-end sample processing and analysis provider to the life sciences market. Our advanced LeviCell system is a groundbreaking cellular research and analysis tool for scientists, researchers, and labs. For the first time ever, researchers can examine, analyze and understand true biological signatures without altering, stressing, or damaging cells—all while preserving the original samples. LeviCell delivers true biology for real cellular insights to power cellular research.

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships. EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.

Cellular Research, Inc., is a pioneering biotechnology research and development company founded in 2011 by innovators from Silicon Valley and Stanford University. Our mission is to revolutionize life science research by enabling high resolution investigation of single cells and limited samples. Our first two product lines Pixel and Precise deliver the power of Molecular Indexing to customers interested in high accuracy and precision for Gene Expression Studies.